Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Virus Like Particles
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Portage Biotech
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : PORT-5 (STI-001), offers a potentially first-in-class approach to developing molecules that activate the STING pathway by packaging a STING agonist in a virus-like particle (VLP), a well-tested delivery system that can be customized and targeted to speci...
Brand Name : PORT-5
Molecule Type : Large molecule
Upfront Cash : Not Applicable
March 09, 2022
Lead Product(s) : Virus Like Particles
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Portage Biotech
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : STI-001
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Portage Biotech
Deal Size : $0.9 million
Deal Type : Financing
Portage Makes Additional Investment in Stimunity S.A.S
Details : Stimunity has reached a major milestone in its preclinical development plan and the additional financing will enable it to start the manufacturing of its biologic cGAMP-VLP (STI-001) lead compound.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
May 11, 2020
Lead Product(s) : STI-001
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Portage Biotech
Deal Size : $0.9 million
Deal Type : Financing
LOOKING FOR A SUPPLIER?
Reset All
